• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Carrot Enters Global Market for Tobacco Cessation with it’s CE Marked Breath Sensor

by Jasmine Pennic 12/22/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Carrot Enters Global Market for Tobacco Cessation with it’s CE Marked Breath Sensor

What You Should Know:

– Digital health company Carrot has obtained CE Mark Certification for its breath sensor, marking its official entry into the global market for tobacco cessation.

– Clinically proven to increase the motivation to quit, the company’s device is the first-ever FDA-cleared breath sensor for consumer use.


Carrot, a Redwood City, CA-based digital health company that delivers clinically proven, behavioral science-based solutions that empower people to take control of their health, today announced it has obtained the CE (Conformité Européenne) Mark for its breath sensor. The CE Mark indicates compliance with health, safety, and environmental protection standards for products sold within the European Economic Area. The breath sensor is a core component of Carrot’s first product, Pivot: a digital platform that enables anyone to quit smoking at their own pace through an easy-to-use app, interactive sensor, human coaching, and behavioral science. 


How Carrot’s Breath Sensor Works

Carrot’s breath sensor allows Pivot members to track their progress towards quitting and become more educated about how their carbon monoxide (CO) values are affected by their smoking behavior. The device is the only CO breath sensor cleared by the FDA for personal, over-the-counter use in the United States and Pivot users who sync the device to the Pivot app are over two times more likely to successfully quit. Obtaining the CE Mark for the device represents a major milestone in Carrot’s mission to expand the reach of the Pivot platform. 

Breath Sensor Clinical Trial Results

Recently, Carrot’s breath sensor was evaluated in a 3-month clinical trial of 200+ individuals who smoke cigarettes. During the trial, participants’ readiness to quit jumped from 15% to 48%, proving that the breath sensor increases the motivation to quit and leads to more quit attempts. More than 90% of trial participants indicated the breath sensor taught them about their CO levels and smoking behavior, and nearly 3 out of 4 reported that seeing their CO values made them want to quit smoking. 

Why It Matters

Despite widespread knowledge of the dangers of tobacco use, quitting smoking is a difficult and complex ordeal for many. CDC data from 2018 indicates that fewer than 1 in 10 adult cigarette smokers in the U.S. succeed in quitting each year. “For the first time, people who smoke no longer have to view quitting as an overwhelming, all or nothing event,” said David S. Utley, M.D., CEO of Carrot. “The Pivot platform welcomes anyone who smokes — whether or not they’re currently ready to quit — and the breath sensor is clinically proven to motivate them to quit, while also allowing them to track their progress throughout their quitting journey.”  

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: behavior, Clinical Trial, digital health, FDA

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |